LY450139

DRUG3 trials

Sponsors

Eli Lilly and Company

Conditions

Alzheimer DiseaseAlzheimer's Disease

Phase 1

A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.

CompletedNCT00765115

Eli Lilly and CompanyAlzheimer Disease

Start: 2006-07-31End: 2007-09-30Updated: 2008-10-02

Phase 3

Effect of LY450139 on the Long Term Progression of Alzheimer's Disease

CompletedNCT00594568

Eli Lilly and CompanyAlzheimer's Disease

Start: 2008-03-31End: 2011-05-31Updated: 2015-03-17

Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo

CompletedNCT00762411

Eli Lilly and CompanyAlzheimer's Disease

Start: 2008-09-30End: 2011-04-30Updated: 2015-02-16

Related Papers

A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans.

2016-03-0717 citations

Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's disease.

2015-06-1037 citations

Alzheimer’s disease progression by geographical region in a clinical trial setting

Alzheimer s Research & Therapy2015-05-1335 citations

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

New England Journal of Medicine2013-07-241196 citations